Quick  links

“Link to Industry: Meet the End User”

Workshop

Tuesday, 23rd of May, 2017

Technology transfer is the tool that helps developing countries facilitates economic growth. This work shop aimed, to promote the engagements of TBRI research, innovation and technology with industry by enhancing the collaborative efforts between key actors in scientific, industrial and governmental sectors, also by getting feedback from industry representatives to facilitate effective collaboration. The workshop focused on exploring problems facing the transfer of R&D products from academia to the market; specifically health products which constitute one of the biggest promising market products in the Middle East. Also, to properly interface with industry TBRI R&D capabilities were presented to make for the lack of resource knowledge between academia and industry

Enhance approval of the clinical trials law.
Create strong links with industry by availing industry needs to scientists and also research skills, facilities and equipment available at different institutions to industry through:

Web site
Meetings and Workshops
Industry representatives should be among TICO governance structure

Heath products regulatory authority to:
Avail guiding place/ office that well inform regarding precise requirements for validation/ accreditation and registration of new medical products; specifically locally developed products.
 Reconsider steps necessary for registration  to avoid Bureaucracy and to facilitate the process of drug registration (the process takes < 2 years for an already FDA approved drugs; industry people say(

ASRT alliances proposals to be encouraged and to involve all key players: Drug Companies, Research Institutes, Ministry of Industry and Ministry of Health Representatives to handle R&D from the laboratory to the market competently and in the shortest time possible.
To encourage drug companies adopt nationally developed R&D products, a shorter pathway for registration and approval of nationally developed innovative health products should be created to bypass the lengthy process if locally developed products are going to be enrolled among all products.
Information from end user (Drug Companies and Patients) regarding banging health needs with respect to country plan 2030 should be availed to scientists; scientists should start by the end user and end by the end user.
Encourage health product companies to adopt products based on local R&D by availing privilege (eg. tax allowances and incentives).
To organize, regulate and facilitate transfer of health products R& D from research to industry an oversight body involving key players (governmental authorities from affiliated ministries, industry representatives and academia) should be created at national level.

Eng.Abdalla Farahat